Lokelma is manufactured by AstraZeneca [1]. It is a treatment for hyperkalemia [1].
What is Lokelma used for?
Lokelma, also known by its generic name sodium zirconium cyclosilicate, is a medication used to reduce high potassium levels in the blood, a condition called hyperkalemia [1]. It works by binding to potassium in the gastrointestinal tract, preventing its absorption into the bloodstream and facilitating its excretion from the body [2].
How does Lokelma work?
The active ingredient in Lokelma, sodium zirconium cyclosilicate, is an inorganic powder that acts as an ion exchanger. In the gut, it selectively binds to potassium ions and releases sodium ions. This binding action traps potassium within the intestinal lumen, from which it is eliminated in the stool [2].
When was Lokelma approved?
Lokelma received approval from the U.S. Food and Drug Administration (FDA) in December 2018 for the treatment of hyperkalemia in adults [1].
Are there alternatives to Lokelma for hyperkalemia?
Other medications are available to manage hyperkalemia. Patiromer is another potassium binder that works similarly by exchanging potassium for calcium in the gut. The choice between Lokelma and other treatments may depend on individual patient needs, physician preference, and the specific clinical situation [3].
What is the patent status for Lokelma?
Information regarding the specific patent status and expiry dates for Lokelma can be found on patent tracking websites such as DrugPatentWatch.com [4]. These resources detail patent filings, grants, and potential litigation that could affect market exclusivity [4].